With AMD3100, a specific antagonist of the CXCL12 receptor CXCR4, this hypothesis was tested in experimental autoimmune encephalomyelitis (EAE) (McCandless et al., 2006). This evidence concerns the gene CXCR4 and experimental autoimmune encephalomyelitis.